 |
 |
 |
Sai Parenterals IPO is a Book Built Issue aggregating up to 408 crore 78 lakh 88 thousand 8 hundred ninety-six rupees. The issue consists of a fresh issue of 72,70,408 shares (aggregating up to 284 crore 99 lakh 99 thousand 9 hundred thirty-six rupees) and an offer for sale of 31,57,880 shares (aggregating up to 123 crore 78 lakh 88 thousand 9 hundred sixty rupees).
The IPO opened for subscription on 24 March 2026 and closes on 27 March 2026. The basis of allotment will be finalized on 30 March 2026. The shares will be listed on NSE, BSE on 2 April 2026.
The price band for the IPO is set at ₹372 to ₹392 per share per share. The minimum amount required for a retail investor is ₹14,896 (38 shares, 1 lot). The minimum amount required for an sHNI investor is ₹2,08,544 (532 shares, 14 lots).
Arihant Capital Markets Ltd is the lead manager and Bigshare Services is the registrar of the IPO.
Refer to Sai Parenterals IPO RHP for more detailed information.
IPO Details Live
IPO Date
24 March 2026 to 27 March 2026The opening and closing dates during which investors can apply for the IPO.
Listing Date
2 April 2026The date when shares start trading on the stock exchanges.
Face Value
₹5 per shareThe nominal value of a security stated in the company books. Mainly used as the base for dividends and accounting
Price Band
₹372 to ₹392 per shareThe minimum and maximum price range within which investors can bid for IPO shares.
Lot Size
38 sharesThe minimum number of shares an investor must apply for in a single IPO application.
Issue Type
Book Built Issue The method used to price the IPO. In a Book Built Issue, the price is determined by investor demand within the price band.
Listing At
NSE, BSEThe stock exchange(s) where the company shares will be officially listed and traded.
IPO Issue Details
Issue Size
1,04,28,288 shares (₹4,08,78,88,896)Total number of shares multiplied by the issue price.
Issue (Sale Type)Fresh issue and Offer for sale
Fresh Issue72,70,408 shares (₹2,84,99,99,936)
Offer for Sale31,57,880 shares (₹1,23,78,88,960)
Share Holding (Pre Issue)3,69,08,823 shares
Share Holding (Post Issue)4,41,79,231 shares
The Sai Parenteral's IPO is a mainboard IPO with issue size 1,04,28,288 shares (aggregating up to 408 crore 78 lakh 88 thousand 8 hundred ninety-six rupees). The issue is priced at ₹372 to ₹392 per share and is a mix of a fresh issue of 72,70,408 shares (aggregating up to 284 crore 99 lakh 99 thousand 9 hundred thirty-six rupees) and an offer for sale of 31,57,880 shares (aggregating up to 123 crore 78 lakh 88 thousand 9 hundred sixty rupees).
Sai Parenterals IPO Lot Size & Required Amount
Sai Parenterals IPO has set a price band of per share and lot size is of shares.
Retail investors can bid for a minimum of 1 lot (38 shares), requiring minimum investment of ₹14,896,
and maximum upto 13 lots (494 shares), requiring maximum investment of ₹1,93,648.
Small HNI investors can bid for a minimum of 14 lots (532 shares), requiring an investment of ₹2,08,544,
small hni (sHNI) investors can bid for a maximum of 67 lots (2546 shares), requiring an investment of ₹9,98,032 and big hni (bHNI) investors can bid for a minimum of 68 Lots (2584 shares), requiring an investment of ₹10,12,928.
Calculated at the cut-off price ₹ per share (the upper end of the price band).
Number of Shares Per Lot = Shares
| Application | Lot(s) | Shares | Amount |
|---|---|---|---|
|
Retail (Min) Minimum investment required for Retail Individual Investors (RII). |
1 | 38 | ₹14,896 |
|
Retail (Max) Maximum investment allowed for Retail Individual Investors (Must be under ₹2 Lakhs). |
13 | 494 | ₹1,93,648 |
|
S-HNI (Min) Minimum investment for Small High Net-worth Individuals (sHNI) (Must be above ₹2 Lakhs). |
14 | 532 | ₹2,08,544 |
|
S-HNI (Max) Maximum investment for Small High Net-worth Individuals (sHNI) (Must be up to ₹10 Lakhs). |
67 | 2546 | ₹9,98,032 |
|
B-HNI (Min) Minimum investment for Big High Net-worth Individuals (bHNI) (Must be above ₹10 Lakhs). |
68 | 2584 | ₹10,12,928 |
IPO Reservation
Sai Parenteral's IPO offers total 1,04,28,288 shares (100.00%) . Out of which 52,14,144 shares (50.00%) allocated to QIB, 20,85,659 shares (20.00%) allocated to QIB (Ex- Anchor), 15,64,243 shares (15.00%) allocated to NII and 31,28,485 shares (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered |
|---|---|
|
QIB Shares Offered
Qualified Institutional Buyers (e.g., mutual funds, banks). |
52,14,144 shares (50.00%) |
|
-
QIB (Anchor Investor)
A portion of QIB shares reserved specifically for anchor investors. |
31,28,485 shares (30.00%) |
|
-
QIB (Ex. Anchor)
Remaining QIB shares after anchor investor allocation. |
20,85,659 shares (20.00%) |
|
NII (HNI) Shares Offered
Non-Institutional Investors, also known as High Net-worth Individuals. |
15,64,243 shares (15.00%) |
|
-
bNII (bids > ₹10L)
Big HNI category for applications above ₹10 Lakhs. |
10,42,829 shares (10.00%) |
|
-
sNII (bids < ₹10L)
Small HNI category for applications between ₹2 Lakh and ₹10 Lakh. |
5,21,414 shares (5.00%) |
| Total Shares Offered | 1,04,28,288 shares (100.00%) |
IPO Anchor Investors
Sai Parenteral's IPO raises ₹122.64 crore from anchor investors. Sai Parenteral's IPO anchor bid date was 23 March 2026.
Bid Date
The date on which anchor investors can bid for the shares.
23 March 2026
Shares Offered
Total number of shares allocated specifically to anchor investors.
31,28,485 shares
Anchor Portion (₹ Cr.)
Total value of the shares allocated to anchor investors in crores.
122.64
Sai Parenterals Financials (Restated Consolidated)
Annual Performance (31 Mar 25 vs 31 Mar 24)
Sai Parenterals Financials (Restated Consolidated)'s Assets increased by 1.6%, Revenue increased by 5.5%, Profit After Tax increased by 71.4%, EBITDA increased by 24.4%, Net Worth increased by 25.4%, Total Borrowing dropped by 20.9%, Reserves & Surplus increased by 31.1% compared to the previous financial year.
Assets
▲ 1.6%
(4.29)
Revenue
▲ 5.5%
(8.56)
Profit After Tax
▲ 71.4%
(6.01)
EBITDA
▲ 24.4%
(7.74)
Net Worth
▲ 25.4%
(19.38)
Total Borrowing
▼ 20.9%
(-24.84)
Reserves & Surplus
▲ 31.1%
(19.06)
Previous Financial Year Growth (31 Mar 24 vs 31 Mar 23)
Comparing 31 Mar 24 with 31 Mar 23, Assets increased by 100.1%, Revenue increased by 59.9%, Profit After Tax increased by 92.2%, EBITDA increased by 79.7%, Net Worth increased by 142.6%, Total Borrowing increased by 73.3%, Reserves & Surplus increased by 151.8%.
Assets (Prev Yr)
▲ 100.1%
(134.14)
Revenue (Prev Yr)
▲ 59.9%
(58.15)
Profit After Tax (Prev Yr)
▲ 92.2%
(4.04)
EBITDA (Prev Yr)
▲ 79.7%
(14.06)
Net Worth (Prev Yr)
▲ 142.6%
(44.91)
Total Borrowing (Prev Yr)
▲ 73.3%
(50.24)
Reserves & Surplus (Prev Yr)
▲ 151.8%
(36.96)
2-Year Performance Change (31 Mar 23 To 31 Mar 25)
Between 31 Mar 25 and 31 Mar 23, Assets increased by 103.3%, Revenue increased by 68.8%, Profit After Tax increased by 229.5%, EBITDA increased by 123.6%, Net Worth increased by 204.2%, Total Borrowing increased by 37.1%, Reserves & Surplus increased by 230.2%.
Assets (2-Yr Change)
▲ 103.3%
(138.43)
Revenue (2-Yr Change)
▲ 68.8%
(66.71)
Profit After Tax (2-Yr Change)
▲ 229.5%
(10.05)
EBITDA (2-Yr Change)
▲ 123.6%
(21.8)
Net Worth (2-Yr Change)
▲ 204.2%
(64.29)
Total Borrowing (2-Yr Change)
▲ 37.1%
(25.4)
Reserves & Surplus (2-Yr Change)
▲ 230.2%
(56.02)
| 30 Sep 25 In Cr. | 31 Mar 25 In Cr. | 31 Mar 24 In Cr. | 31 Mar 23 In Cr. | |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.1 | 133.96 |
| Revenue | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.7 | 17.64 |
| Net Worth | 209.37 | 95.78 | 76.4 | 31.49 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
| Reserves & Surplus | 188.84 | 80.36 | 61.3 | 24.34 |
Financial Performance Indicator (FPI)
| FPI | 30 Sep 2025 | 31 Mar 2025 |
|---|---|---|
ROE Return on Equity (ROE) is a measure of financial performance... | 5.13% | 16.82% |
ROCE Return on Capital Employed indicates how efficiently a company uses its capital. | 9.28% | 28.92% |
| RoNW | 5.09% | 15.09% |
| PAT Margin | 8.93% | 8.88% |
| EBITDA Margin | 18.68% | 24.18% |
| Price to Book Value | 10.89 |
| Pre IPO | Post IPO | |
|---|---|---|
EPS Rs Earnings Per Share is a company's profit divided by outstanding shares. | 5.43 | |
| P/E (x) | 72.19 | |
| Promoter Holding | 61.23% | 51.2% |
Market Cap Total market value of a company's outstanding shares. | ₹1,731.83 crore | |
IPO Peer Comparison
| Company Name | P/E ratio | EPS (Basic) | EPS (Diluted) | NAV (per share) | RoNW (%) | P/BV |
|---|---|---|---|---|---|---|
| Gland Pharma | 44.71(Gland) | 42.40(Gland) | 42.40(Gland) | 555.41(Gland) | 7.63(Gland) | 2.87(Gland) |
| Senores Pharmaceuticals | 64.30(Senores) | 16.12(Senores) | 16.12(Senores) | 176.37(Senores) | 7.18(Senores) | 3.24(Senores) |
| Innova Captab | 32.45(Innova) | 22.41(Innova) | 22.41(Innova) | 167.66(Innova) | 13.37(Innova) | 5.26(Innova) |
| Sai Life Sciences | 107.70(Sai) | 8.83(Sai) | 8.61(Sai) | 102.12(Sai) | 7.99(Sai) | 7.45(Sai) |
| Sai Parenteral's | (Sai) | 5.43(Sai) | 5.43(Sai) | 35.98(Sai) | 15.09(Sai) | (Sai) |
IPO Subscription Status
Loading Latest IPO Data...
Sai Parenterals IPO Lead Manager(s)
- Arihant Capital Markets Ltd